EGFR and adenocarcinoma: In addition, while not significantly decreased in the overall NSCLC-BM cohort, EGFR exon19 deletions, and EGFR L858R mutations were significantly decreased in the NSCLC-BM with adenocarcinoma histology when compared to the pNSCLC with adenocarcinoma histology (both P = .001).